Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 60

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 60
---
, the retention value of existing holdings, individual performance, role criticality, expected future contribution, disclosure requirements, the Company’s compensation philosophy, proxy advisory firm position and internal equity. The following table sets forth the stock options granted to our named executive officers in 2024:

| Named Executive Officer   | ​ | ​ | Grant Date |   |           |   | ​ | ​ | Number of SharesUnderlying StockOptions |   |            |   | ​ |
| Jasbir Seehra, Ph.D.      | ​ | ​ | ​          | ​ | ​(1)      | ​ | ​ | ​ | ​                                       | ​ | 250,000(1) | ​ | ​ |
| Simon Cooper, M.B.B.S.(2) | ​ | ​ | ​          | ​ | 2/13/2024 | ​ | ​ | ​ | ​                                       | ​ |     40,000 | ​ | ​ |
| Keith Regnante            | ​ | ​ | ​          | ​ | 2/13/2024 | ​ | ​ | ​ | ​                                       | ​ |     40,000 | ​ | ​ |
| Christopher Rovaldi       | ​ | ​ | ​          | ​ | 2/13/2024 | ​ | ​ | ​ | ​                                       | ​ |    150,000 | ​ | ​ |

(1) 50% of Dr. Seehra’s 2024 annual equity award (125,00 shares), granted on February 23, 2024, was delivered in the form of a performance-vesting stock option that vests based on achievement of two rigorous pipeline development objectives. The remaining 50% of his 2024 annual equity award (125,000 shares), granted on February 13, 2024, was granted in the form of time-vesting stock options. The performance-vesting portion of the option was granted ten days later than the time-vesting option because the Compensation Committee needed additional time to finalize the terms of the performance goals and as a result, has a higher exercise price per share ($63.61) than the time-vesting portion ($56.18). (2) On February 29, 2024, Dr. Cooper resigned from his position as our Chief Medical Officer, effective March 12, 2024. As a result, all of Dr. Cooper’s outstanding, unexercised options have terminated. In November 2024, in